Ambrx Biopharma, Inc.
AMAMDelisted Mar 7, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001990550
Ambrx Biopharma, Inc. was delisted on Mar 7, 2024; its insiders filed their last Form 4 on Mar 7, 2024; 68 institutions reported holding it in 13F filings for Q4 2023, worth $912.7M in total; no superinvestor held it.
Q3 2021 vs. Q2 2021
How the institutions holding Ambrx Biopharma, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 20 | 15 | −5 |
| Shares | 13.9M | 12.4M | −1.52M (−10.9%) |
| Value | $266.2M | $165.3M | −$100.9M (−37.9%) |
New holders (2)
Institutions that held Ambrx Biopharma, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Morgan Stanley | 2,800 | $38.0K | 0.00% |
| Migdal Insurance & Financial Holdings Ltd. | 200 | $3.00K | 0.00% |
Sold out (7)
Institutions that held Ambrx Biopharma, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Suvretta Capital Management, LLC | 1,169,529 | $22.9M |
| Monashee Investment Management LLC | 110,000 | $2.16M |
| Alliancebernstein L.P. | 70,000 | $1.37M |
| Marshall Wace North America L.P. | 32,648 | $640.0K |
| Parkman Healthcare Partners LLC | 15,000 | $294.0K |
| Boothbay Fund Management, LLC | 13,422 | $263.0K |
| Pinz Capital Management, LP | 1,000 | $20.0K |